Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:CRNX NASDAQ:IOVA NASDAQ:KYMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$26.04-3.0%$23.50$16.10▼$39.51$3.39B0.732.20 million shs1.73 million shsCRNXCrinetics Pharmaceuticals$35.00-4.1%$30.77$24.10▼$62.53$3.44B0.281.03 million shs1.17 million shsIOVAIovance Biotherapeutics$2.38+0.4%$2.42$1.64▼$12.51$857.59M0.8211.07 million shs11.17 million shsKYMRKymera Therapeutics$43.48$43.33$19.44▼$53.27$3.11B2.17616,664 shs647,042 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals-0.26%-4.72%+10.14%+39.28%-32.80%CRNXCrinetics Pharmaceuticals+3.87%+9.61%+35.94%+12.90%-30.13%IOVAIovance Biotherapeutics-0.42%+8.22%+12.32%+5.80%-75.96%KYMRKymera Therapeutics+0.51%+6.86%+7.04%-10.15%-5.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$26.04-3.0%$23.50$16.10▼$39.51$3.39B0.732.20 million shs1.73 million shsCRNXCrinetics Pharmaceuticals$35.00-4.1%$30.77$24.10▼$62.53$3.44B0.281.03 million shs1.17 million shsIOVAIovance Biotherapeutics$2.38+0.4%$2.42$1.64▼$12.51$857.59M0.8211.07 million shs11.17 million shsKYMRKymera Therapeutics$43.48$43.33$19.44▼$53.27$3.11B2.17616,664 shs647,042 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals-0.26%-4.72%+10.14%+39.28%-32.80%CRNXCrinetics Pharmaceuticals+3.87%+9.61%+35.94%+12.90%-30.13%IOVAIovance Biotherapeutics-0.42%+8.22%+12.32%+5.80%-75.96%KYMRKymera Therapeutics+0.51%+6.86%+7.04%-10.15%-5.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.58Moderate Buy$34.1231.02% UpsideCRNXCrinetics Pharmaceuticals 2.78Moderate Buy$68.8696.73% UpsideIOVAIovance Biotherapeutics 2.36Hold$11.90400.00% UpsideKYMRKymera Therapeutics 3.06Buy$58.7635.15% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, APLS, CRNX, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/12/2025IOVAIovance BiotherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/11/2025CRNXCrinetics PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$90.00 ➝ $86.008/8/2025IOVAIovance BiotherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$18.00 ➝ $14.008/8/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $20.008/4/2025APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.008/1/2025APLSApellis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$17.00 ➝ $19.008/1/2025APLSApellis PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$39.00 ➝ $40.008/1/2025APLSApellis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$52.00 ➝ $50.007/30/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$60.007/29/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $46.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M4.21N/AN/A$1.84 per share14.15CRNXCrinetics Pharmaceuticals$1.04M3,169.52N/AN/A$14.29 per share2.45IOVAIovance Biotherapeutics$164.07M5.25N/AN/A$2.33 per share1.02KYMRKymera Therapeutics$47.07M66.05N/AN/A$12.90 per share3.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/11/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)Latest IOVA, APLS, CRNX, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 million7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.903.773.16CRNXCrinetics PharmaceuticalsN/A17.8017.80IOVAIovance BiotherapeuticsN/A3.272.89KYMRKymera TherapeuticsN/A8.328.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%CRNXCrinetics Pharmaceuticals98.51%IOVAIovance Biotherapeutics77.03%KYMRKymera TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%CRNXCrinetics Pharmaceuticals4.60%IOVAIovance Biotherapeutics10.30%KYMRKymera Therapeutics16.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770126.29 million118.08 millionOptionableCRNXCrinetics Pharmaceuticals21094.18 million89.84 millionOptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionableIOVA, APLS, CRNX, and KYMR HeadlinesRecent News About These CompaniesKymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9 at 5:01 PM | seekingalpha.comKymera Therapeutics, Inc. $KYMR Shares Sold by Cinctive Capital Management LPSeptember 8 at 5:47 AM | marketbeat.comBrokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $58.76September 8 at 2:51 AM | americanbankingnews.comWhy Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?September 7 at 5:12 PM | msn.comNorthern Trust Corp Lowers Stock Position in Kymera Therapeutics, Inc. $KYMRSeptember 7 at 3:32 AM | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 7 at 3:09 AM | marketbeat.comKymera Therapeutics Announces New Chief Legal OfficerSeptember 6, 2025 | theglobeandmail.comEventide Asset Management LLC Grows Position in Kymera Therapeutics, Inc. $KYMRSeptember 6, 2025 | marketbeat.comCheckpoint Capital L.P. Has $3.74 Million Stock Position in Kymera Therapeutics, Inc. $KYMRSeptember 6, 2025 | marketbeat.com10,059 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Walleye Capital LLCSeptember 6, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Up 5.7% - Here's WhySeptember 5, 2025 | marketbeat.comRedmile Group LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comKymera Therapeutics appoints Adams as Chief Legal Officer, Corporate SecretarySeptember 3, 2025 | msn.comKymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate SecretarySeptember 3, 2025 | globenewswire.comInvesco Ltd. Has $1.15 Million Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 3, 2025 | marketbeat.com122,605 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Yiheng Capital Management L.P.September 1, 2025 | marketbeat.comKymera Therapeutics, Inc. $KYMR Shares Sold by Driehaus Capital Management LLCSeptember 1, 2025 | marketbeat.comNuveen LLC Purchases Shares of 143,238 Kymera Therapeutics, Inc. $KYMRAugust 30, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 60,000 Shares of Kymera Therapeutics, Inc. $KYMRAugust 28, 2025 | marketbeat.comKymera Therapeutics, Inc. $KYMR Shares Bought by Russell Investments Group Ltd.August 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOVA, APLS, CRNX, and KYMR Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$26.04 -0.80 (-2.98%) Closing price 04:00 PM EasternExtended Trading$25.94 -0.09 (-0.36%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Crinetics Pharmaceuticals NASDAQ:CRNX$35.00 -1.50 (-4.11%) Closing price 04:00 PM EasternExtended Trading$34.20 -0.80 (-2.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Iovance Biotherapeutics NASDAQ:IOVA$2.38 +0.01 (+0.42%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.03 (-1.47%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Kymera Therapeutics NASDAQ:KYMR$43.48 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$43.49 +0.01 (+0.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
